ATIP · Ati Physical Therapy, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $189.99M | $188.11M | $181.47M | - | $177.46M | $172.34M | $166.93M | - | $156.79M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | $23.77M | $23.08M | $26.20M | - | $25.09M | $36.57M | $30.59M | - | $25.26M |
| Total Operating Expenses | - | $164.97M | $158.14M | $159.57M | - | $153.13M | $148.12M | $147.71M | - | $144.52M |
| D&A | - | $8.61M | $8.33M | $8.88M | - | $9.12M | $9.16M | $9.69M | - | $9.92M |
| Operating Income | - | $1.13M | $6.63M | ($4.78M) | - | ($764.0K) | ($12.36M) | ($11.37M) | - | ($119.66M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | ($128.0K) | ($13.0K) | ($134.0K) | - | $131.0K | $89.0K | $62.0K | - | ($7.22M) |
| Net Income | - | ($33.81M) | ($3.73M) | ($14.65M) | - | ($15.20M) | ($22.70M) | ($26.27M) | - | ($116.32M) |
| EPS - Basic | - | ($9.38) | ($2.43) | ($4.61) | - | ($4.42) | ($17.74) | ($0.15) | - | ($0.60) |
| EPS - Diluted | - | ($9.38) | ($2.43) | ($4.61) | - | ($4.42) | ($17.74) | ($0.15) | - | ($0.60) |
Balance Sheet
| Line item | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $39.08M | $23.46M | $32.96M | $23.73M | $36.80M | $19.73M | $37.68M | $63.08M | $83.14M | $48.57M |
| Accounts Receivable | $101.97M | $99.97M | $100.04M | $100.52M | $88.51M | $84.97M | $80.78M | $82.21M | $80.67M | $82.32M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $18.20M | $16.73M | $10.93M | $10.86M | $14.70M | $11.46M | $12.54M | $10.24M | $12.56M | $11.10M |
| Current Assets | $157.88M | $160.32M | $176.88M | $166.17M | $168.64M | $123.53M | $138.99M | $166.85M | $194.13M | $157.13M |
| Total Assets | $958.12M | $967.28M | $990.54M | $991.49M | $1.00B | $978.52M | $1.01B | $1.05B | $1.08B | $1.16B |
| Current Liabilities | $141.16M | $143.66M | $151.21M | $139.72M | $156.45M | $119.42M | $126.46M | $111.22M | $116.52M | $115.98M |
| Long-term Debt | - | - | - | - | - | - | - | $534.14M | $531.60M | $479.91M |
| Total Liabilities | $883.29M | $889.55M | $880.15M | $879.88M | $878.74M | $851.20M | $869.59M | $884.95M | $890.20M | $864.50M |
| Stockholders' Equity | ($176.34M) | ($166.01M) | ($127.35M) | ($118.62M) | ($101.00M) | ($94.18M) | ($78.08M) | $15.63M | $43.96M | $147.43M |
| Retained Earnings | ($1.47B) | ($1.46B) | ($1.43B) | ($1.42B) | ($1.41B) | ($1.40B) | ($1.39B) | ($1.37B) | ($1.34B) | ($1.24B) |
Cash Flow
| Line item | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($39.07M) | - | - | - | ($14.22M) | - | - |
| Investing Cash Flow | - | - | - | ($2.49M) | - | - | - | ($5.08M) | - | - |
| Financing Cash Flow | - | - | - | $28.48M | - | - | - | ($761.0K) | - | - |
| CapEx | - | - | - | $2.67M | - | - | - | $5.43M | - | - |
| Free Cash Flow | - | - | - | ($41.74M) | - | - | - | ($19.66M) | - | - |
Ratios
| Metric | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | 0.6% | 3.5% | -2.6% | - | -0.4% | -7.2% | -6.8% | - | -76.3% |
| EBITDA margin | - | 5.1% | 8.0% | 2.3% | - | 4.7% | -1.9% | -1.0% | - | -70.0% |
| Net margin | - | -17.8% | -2.0% | -8.1% | - | -8.6% | -13.2% | -15.7% | - | -74.2% |
| Free cash flow margin | - | - | - | -23.0% | - | - | - | -11.8% | - | - |
| FCF / Net income | - | - | - | 2.85 | - | - | - | 0.75 | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | 12.5% | 12.3% | 14.4% | - | 14.1% | 21.2% | 18.3% | - | 16.1% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | - | -3.5% | -0.4% | -1.5% | - | -1.6% | -2.2% | -2.5% | - | -10.1% |
| Return on equity | - | 20.4% | 2.9% | 12.4% | - | 16.1% | 29.1% | -168.0% | - | -78.9% |
| Return on invested capital | - | - | - | - | - | - | - | -1.6% | - | -15.1% |
| Liquidity | ||||||||||
| Current ratio | 1.12 | 1.12 | 1.17 | 1.19 | 1.08 | 1.03 | 1.10 | 1.50 | 1.67 | 1.35 |
| Quick ratio | 1.12 | 1.12 | 1.17 | 1.19 | 1.08 | 1.03 | 1.10 | 1.50 | 1.67 | 1.35 |
| Cash ratio | 0.28 | 0.16 | 0.22 | 0.17 | 0.24 | 0.17 | 0.30 | 0.57 | 0.71 | 0.42 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | 34.16 | 12.09 | 3.26 |
| Debt / Assets | - | - | - | - | - | - | - | 0.51 | 0.49 | 0.41 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -5.43 | -5.83 | -7.78 | -8.36 | -9.93 | -10.39 | -12.94 | 66.89 | 24.55 | 7.85 |
| Liabilities / Assets | 0.92 | 0.92 | 0.89 | 0.89 | 0.88 | 0.87 | 0.86 | 0.85 | 0.83 | 0.75 |
| Efficiency | ||||||||||
| Asset turnover | - | 0.20 | 0.19 | 0.18 | - | 0.18 | 0.17 | 0.16 | - | 0.14 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | 192d | 194d | 202d | - | 175d | 171d | 180d | - | 192d |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | 7.1% | 9.2% | 8.7% | - | 13.2% | 5.5% | - | - | 5.5% |
| Revenue CAGR (3y) | - | 8.5% | 4.7% | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | - | 58.0% | - | 99.4% | 91.2% | - | - | 76.8% |
| Net income growth (YoY) | - | -122.5% | 83.5% | 44.2% | - | 86.9% | 83.2% | - | - | 64.9% |
| EPS growth (YoY) | - | -112.2% | 86.3% | -2973.3% | - | -636.7% | -2471.0% | - | - | 64.3% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | -112.3% | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -74.6% | -76.3% | -63.1% | - | - | - | - | -96.0% | -91.3% | -70.2% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Product / service
$816.17M totalHealth Care Patient Service$689.96M · 84.5%
Product And Service Other$63.10M · 7.7%
ATIWorksite Solutions$36.64M · 4.5%
Management Service Agreements$15.32M · 1.9%
Products And Services Sports Medicine And Other Miscellaneous Revenue$11.15M · 1.4%
Peer comparison
Same SIC group: Services-Nursing & Personal Care Facilities
Comparing ATI Physical Therapy against the 5 most active filers in the same SIC group.